Co-funded by the
European Union

EIT Health Call for Proposals

Transformative Health Instrument 2027

Under EIT Health Business Plan 2026 - 2028

EIT Health

Munich

www.eithealth.eu

Table of Contents

Change Log

All updates to the call document will be captured in the below table. Applicants with applications in draft or submitted status will be informed via email of any changes that occur to the call document during the application period.

Version	Date	Description
1	24 June 2026	Call Document publication
2	03 July 2026	2.2 – Project Purpose – additional text added to clarify the aims of the call 2.4 – Activities and work packages – additional text added explaining requirements for a dissemination plan 5.3 – Evaluation criteria – Strategic fit criteria moved from Excellence category to the category on KIC Portfolio Strategic Fit and Compliance with the Financial Sustainability Principles 5.5 – Requirements for selected proposals – additional text added to clarify the reserve list.

Abbreviations

EIT	European Institute of Innovation and Technology
KIC	Knowledge and Innovation Community
EIT SIA	EIT Strategic Innovation Agenda
PA	Partnership Agreement
HE MGA	Horizon Europe Model Grant Agreement
KIC SA	KIC Strategic Agenda
BP	Business Plan
EIT KPIs	Set of Key Performance Indicators (KPIs) defined by the EIT that reflect the EIT operational objectives for education, entrepreneurship, and innovation. These KPIs are used to measure how effectively a KIC/project meets the objectives of the EIT.
KAVA	KIC-added value activity
FSTP	Financial support to third parties
WP	Work Plan
SME	Small and Medium-sized enterprises (SMEs)
IML	Innovation Maturity Level
RIS	EIT Regional Innovation Scheme (EIT RIS Regions)

Definitions

Knowledge Triangle Integration	The EIT is established to complement existing Union and national policies and initiatives by fostering the integration of the knowledge triangle – higher education, research and innovation, and business creation – across the Union.
Horizon Europe Model Grant Agreement	The Horizon Europe Model Grant Agreement (HE MGA) sets out the rights and obligations and the terms and conditions applicable to the implementation of the EIT grant.
Deliverable	Deliverables are tangible or intangible goods or service produced during the project implementation phase. They track the progress made towards a project's objectives and may take the form of a report, document, software product, course, event or any other building block of a project. The deliverables specified need to fully demonstrate the project's achievements and the judicious use of public funds.

Call Fact Sheet

Call publication	24 June 2026
Open for applications	15 July 2026
Deadline for applications	16 September 2026
Evaluation timeline	• Evaluation of proposals start: 17 September 2026 • Notification of final outcome: 09 December 2026
Project implementation timeline	• Signature of agreements: 01 January 2027 • Project start: 01 January 2027 • Project end: 31 December 2027
Funding amounts	• Overall financial amount of up 5,000,000 EUR available for this Call. • Up to 10 projects may be awarded, subject to the quality of the proposals.
Funding terms	• Funding requested must be between 300,000 and 500,000 EUR maximum per project. • Grant will cover up to 50% of the total project costs, up to the maximum funding described above. • Mandatory Financial Sustainability Contribution Agreement (Grant-to-Options-to-Equity Agreement) to be signed between EIT Health and the grant recipient.
Scope	The THI call seeks SMEs developing innovative solutions in Biotech, MedTech, Digital Health & AI, and Biomarker/Diagnostics sectors. EIT Health will co-fund projects to develop scalable health technologies that address an unmet clinical need in Europe, and that can adapt to diverse healthcare systems, regulatory environments, and cultural contexts in Europe. The solution should have a clear strategy for regulatory approval and clinical evidence collection with potential for widespread adoption and impact across Europe.

Solution eligibility[1]	• Companies should be focused on innovations within the healthcare sector, specifically Biotech, Medtech, Digital Health & AI, Biomarker/Diagnostics or a combination of these.
	• The solutions must be at an Innovation Maturity Level (IML) at the start of the project as indicated below: [2]
	    ○ IML ≥ 5 for Biotech (Safety/Toxicity study stage)
	    ○ IML≥ 6 in Medtech (Initial clinical PoC)

[1] Please see the full scope of eligibility conditions listed in chapter three; Conditions to Receive Funding.
[2] Please refer to EIT Health's Healthcare Innovation Cycle Framework for more information on the required Innovation Maturity Level for this call: https://eithealth.eu/a-framework-for-innovation-in-healthcare/

	○ IML ≥ 7 for Digital (Market validation) ○ IML ≥ 7 for Biomarker Diagnostics
List of call documents	• Call document • Application form, available on the application platform here • Frequently Asked Questions, available here • Project Grant Agreement, available here • Grant-to-Options-to-Equity Agreement, available here • Project implementation handbook, available here
How to apply	• **Step 1:** register your organisation in the EU Funding & tender opportunities portal to obtain the nine-digit Participant Identification Code (PIC number). If you do not know if your organisation already has a PIC number, you can verify directly on the EU Portal (click here) whether your organisation is already registered. • **Step 2:** apply to the call via EIT Health's application platform here.
Events	• **Call introduction webinar**: 15 July 2026, 13.30 CEST**.** Click here to register. • **Open Q&A session:** 02 September 2026, 11.00 CEST Click here to register
Contact	Calls@eithealth.eu

Co-funded by the European Union

1 Introduction

EIT Health is a Knowledge and Innovation Community (KIC) of the European Institute of Innovation and Technology (EIT), an EU body operating under the Horizon Europe framework. Our mission is to strengthen a sustainable healthcare system in Europe by accelerating innovation and building future health leaders (see chapter 10 and 11 for more information).

Europe is capable of unprecedented breakthroughs in science and technology, but companies developing disruptive technologies face a complex, fragmented and rapidly evolving policy and regulatory landscape. This has increased the capital needs for scaling companies, but at the same time, the investment market is still recovering from the market downturn in 2022. Companies currently seeking funding in Europe operate in a complex and competitive investment environment, which presents both a need and an opportunity to strengthen early-stage European investment in healthcare innovation, and to close the gap with Europe's global competitors.

EIT´s Transformative Health Instrument (THI) call is designed to foster the European healthcare innovation ecosystem and drive innovation and competitiveness by supporting high-potential Micro, Small and Medium-sized enterprises (SMEs). The THI offers between 300,000 – 500,000 EUR in grant funding to propel cutting-edge ventures forward and prepare them for the next steps in fundraising, product development and commercialisation.

EIT Health encourages the participation of entities from the EIT Regional Innovation Scheme (EIT RIS Regions) with the goal of improving the Knowledge Triangle integration and the innovation capacity of local ecosystems in RIS countries and regions.

The European Commission is committed to promoting gender equality in innovation and technology. EIT, as a body of the European Union and an integral part of Horizon Europe, and EIT Health share the EIT KIC gender diversity value statement. Consequently, the gender requirements in Horizon Europe are of significant importance for all EIT Health supported and funded activities, including the ones in this call for proposals.

2 Description of the Call Objectives and Scope

2.1 Project Description

The Transformative Health Instrument (THI) call invites micro, small, and medium enterprises (SMEs) to submit applications for funding to support the development of scalable health technologies in Biotech, Medtech, Digital Health & AI, Biomarker / Diagnostics or a combination of these. Applicants should address unmet needs in Europe with novel and commercially viable approaches, scientific excellence, and strong internal capabilities.

Depending on the focus of the company, applicants' solutions must be at the following innovation maturity levels (IML) at the time of application: [3]

- IML ≥ 5 for Biotech (Safety/Toxicity study stage).
- IML≥ 6 in Medtech (Initial clinical PoC).
- IML ≥ 7 for Digital (Market validation).
- IML ≥ 7 for Biomarker Diagnostics.

The following types of innovations are out of scope:

- A non-medical device or application.
- A product primarily designed for wellness or lifestyle purposes that can be used without medical oversight.
- Companies that do not target the European market.

The funded innovation must be premised on a viable existing or future business model and a legally registered, for-profit entity with the proper capabilities to develop, market and scale the solution.

2.2 Project Purpose and Expected Impact

This call aims to strengthen integration between the research and business sides of the knowledge triangle by accelerating healthcare innovations borne out of research to support commercial and business growth of small and micro enterprises in European markets. [4] All funded projects under this Call are expected to generate the following outcomes and long-term impact.

- Commercial acceleration, including attracting additional funding, closing future venture capital investments, and growing revenue (where applicable).
- Developing and accelerating new health innovations with high potential to positively impact the lives of the citizens of Europe, as well as to generate financial returns.

---

[3] Please refer to EIT Health's Healthcare Innovation Cycle Framework for more information on the required Innovation Maturity Level for this call: https://eithealth.eu/a-framework-for-innovation-in-healthcare/

[4] See here for more information on the knowledge triangle - https://eithealth.eu/what-we-do/

- Protection of new innovations and micro, small, and medium enterprises (SME´s) via intellectual property (IP) strategy.

Proposals must clearly and credibly articulate the path to achieving such impact, which may be reported up to three years after the end of the EIT Health funding period. Please refer to sections 2.3.3 on Key Performance Indicators (KPIs) and 7.2 on Monitoring for more information on the contractual obligations of projects to report achieved impacts during and after the project funding period.

Extension or continuation of projects will be tied to the conditions described in section 3.10 Fast Track Mechanism and Additional Project Funding.

2.3 Project Design

Projects should last no longer than 12 months. All proposals must include a comprehensive workplan and budget describing all the required work packages, tasks and costs to successfully carry out the project and achieve the target outcomes.

The plan shall be structured into Work Packages (WPs), each containing clearly defined tasks, milestones, outputs, deliverables, and associated KPIs. Projects will be required to report to EIT Health every six months (months 6 and 12) on the performance of the project. Activity Leaders are asked to report the progress of their deliverables, milestones and KPIs, along with submitting cost reports to ensure eligibility of costs.[5] See section 7.2 for more information on project monitoring.

Work plans must be coherent, credible, and results oriented. EIT Health mandates certain deliverables and KPIs. These deliverables and KPIs must be included and fully described in the proposal to be considered for funding.

2.4 Activities and Work Packages

Project workplans should aim to describe planned activities in as much detail as possible and can be broken down into as many WPs and include as many sub-tasks as relevant to the project.

Applicants are encouraged to build a workplan that is tailored to their specific project context, activities and needs, and to include those WPs and tasks that are considered relevant to the effective execution of their project.

All work packages must have associated tasks, milestones and deliverables, the achievement of which will be assessed at each reporting period. Projects may include as many tasks, milestones and deliverables as are relevant to the workplan.

This call is funded by Horizon Europe, and therefore beneficiaries are required to promote their project and results. It is mandatory that all applications include a work package, with associated milestones and deliverables on marketing, communication and dissemination. The aim of this work package is to promote the activities and results achieved with the funding provided by EIT Health. See section 8.12 Marketing, Communication, Dissemination and Visibility for more information.

[5] Library of Call Appendices - EIT Health

2.5 Key Performance Indicators (KPIs)

All proposals must include a clear KPI plan describing how each KPI will be achieved, monitored, and reported. KPIs must be quantifiable, time-bound, and linked to specific tasks and deliverables. Please refer to this KPI Guidance for more information.

The following KPIs and minimum KPI targets are mandatory and must be included in the proposal. Proposals may include other KPIs from the EIT Health catalogue of KPIs or include additional custom KPIs.

KPI	Definition	Expression	Min. Target	Timeline	Note
EITHE02.4 – Innovation Launched to the Market	Number of innovations launched to the market generating at least EUR 10,000 in sales revenue.	Units (1 Innovation = 1 unit)	1	From project start until 3 years after the end of the funding period.	Projects targeting multiple countries may report more units. This KPI is not mandatory to companies in the biotech track.
EITHE01.1 – Intellectual Property Rights	Number of IP assets filed or registered (patents, trademarks, registered designs, etc.).	Units (Each registered IP asset = 1 unit)	1	During the funding period	At least one IP protection action is expected, unless otherwise justified.
EITHE06.1 – Investment attracted by KIC-supported start- ups and scale-ups	Total amount of investment raised from public or private sources	Euros	500,000 EUR	From project start until 3 years after the end of the funding period.	Companies should be successfully closing subsequent funding rounds.
KIC13 – Number of citizens/patients that benefitted from solutions developed or implemented	Number of end users (patients or citizens) who benefit from the implemented solution.	Units (1 Patient or citizen = 1 unit).	150,000	Number of citizens/patients that benefitted from solutions developed or implemented within 3 years post-funding	This KPI does not apply to companies in the biotech track.

3 Call Criteria

Following the deadline for submission, the admissibility, eligibility, exclusion and selection criteria checks will be performed for each proposal in line with the following criteria. Only proposals satisfying all the admissibility and eligibility criteria shall pass on to the selection and evaluation stages.

3.1 Application Admissibility

Only proposals satisfying all the admissibility criteria below shall pass on to the eligibility criteria assessment stage.

- Applications must be submitted before the call deadline of 16 September 2026, 16.00 CEST. Any proposals submitted after the deadline will be inadmissible.
- Applications must be submitted using the application platform. Applications submitted through other means will be inadmissible.
- Applications must use a valid Participant Identification Code (PIC code).
    - To obtain a PIC code, register your organisation in the EU Funding & tender opportunities portal to obtain the nine-digit Participant Identification Code (PIC number). If you do not know if your organisation already has a PIC Code, you can verify directly on the EU Portal (click here) whether your organisation is already registered.
    - Please ensure that the PIC code belongs to the entity that will be incurring costs for the proposed project. This is important if the applying entity is part of a holding structure.
- All upload templates provided in the application platform must be used and unaltered. Uploads that do not use the templates where provided will be inadmissible.

3.2 Application Eligibility Conditions

Only proposals complying with all the following conditions will be considered eligible and move to the external evaluation stage.

3.2.1 Entities eligible to participate

For this call, a 'legal entity' means a legal entity created and recognised as such under national law, EU law or international law, which has legal personality and which may, acting in its own name, exercise rights and be subject to obligations, or an entity without legal personality.

3.2.2 Entities eligible for funding

In accordance with the Horizon Europe Work Programme 2025 [6], to be eligible for funding, the applicant must be established in one of the eligible countries, specifically:

- the Member States of the European Union, including their outermost regions;

[6] https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/horizon/wp-call/2025/wp-14-general-annexes_horizon-2025_en.pdf

- the Overseas Countries and Territories (OCTs) linked to the Member States; [7]
- countries associated to Horizon Europe; [8] or,
- certain low- and middle-income countries.[9]

Individuals cannot apply for funding under this call.

3.3 SME Eligibility

Companies must meet the below conditions to be eligible for funding. Only companies satisfying all the below criteria will move to the evaluation stage. The following requirements and definitions shall apply to all applicants:

- The entity is a legally registered for-profit micro, small, or medium enterprise according to the European Commission SME definition.
    - The entity must have at least 4 full-time equivalent (FTE), permanent employees who are compensated on a salaried basis, and are contracted to spend at least 50% of their total working time for the entity at the time of proposal submission. Staff hired as consultants or freelancers are not counted as permanent or salaried staff. The employment status of staff must be demonstrable through payroll records and employment contracts with the company upon request. This condition does not apply to the company Chief Executive Officer (CEO).
    - The entity must have a CEO engaged on a full-time basis at the time of proposal submission. The CEO may be employed under an employment contract or engaged through an equivalent full-time arrangement (e.g. director mandate, management services agreement, founder-director role, or secondment), provided that the CEO is fully dedicated to the entity's operations. Evidence of such engagement (e.g. employment contract, service agreement, appointment documentation or equivalent) must be available upon request.
    - The entity cannot have publicly traded shares or be in the process of an Initial Public Offering (IPO).
    - The assessment of the entity should be done at the parent (holding) company level, if the governance structure of the SME involves a holding structure.
- The company must have successfully closed an equity funding round (Qualified Investment Round) in the last 36 months by the application deadline, where the round meets the following conditions: [10]

---

[7] Entities from Overseas Countries and Territories (OCT) are eligible for funding under the same conditions as entities from the Member States to which the OCT in question is linked. See the Horizon Europe Programme Guide on the portal for a complete list of OCTs.

[8] Please see the Horizon Europe Programme Guide on the Funding and Tenders Portal for up-to-date information on the current list of and the position for Associated Countries: https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/horizon/guidance/programme-guide_horizon_en.pdf

[9] See the Horizon Europe Programme Guide on the Funding and Tenders Portal for a complete list of these countries. List of participating countries in Horizon Europe.

[10] The application deadline is 24 June 2026. The Qualified Investment Round must therefore have been closed between 24 June 2023 and 24 June 2026.

  - A minimum total investment of 2,000,000 EUR within a 36-month period, with at least one new investor contributing.
  - At least one of the new investors in the Qualified Investment Round must be a qualified, privately managed, profit-oriented, professional investor investing from a fund backed by Limited Partner (LP) commitments, including but not limited to independent European venture capital firms, firms managing alternative investment funds, and those investing private capital in early- and growth-stage technology companies.
  - The Qualified Investment Round must be a priced round with a set valuation. Funding rounds via a convertible note or Simple Agreement for Future Equity (SAFE) do not qualify.
- The table below details the documentation that must be uploaded to the application platform for eligibility confirmation. Failure to provide any of the following documents and meet the eligibility conditions to EIT Health's satisfaction will lead to application´s rejection. All documentation should be provided at the parent (holding) company level, if applicable. Please ensure the documents uploaded follow the required file naming convention detailed in the table below.

#	Document name	File name
1	Legal Self-Assessment Certificate and documentation	CompanyName_THI26_Legal Self-Assessment_01 Numbers are only added if there are multiple files. This also applies for the following names.
2	List of commercial agreements signed with third parties, if applicable	CompanyName_ THI26_commercial agreements _name of agreement_01
3	Financial projection in the form of a Profit & Loss table, value creation plan, and latest Capitalisation table. • Please fill in and submit all tabs included in the financial template Excel file that is available to download in the application platform. • Capitalisation Table must show the pre-money and post-money ownership structures before and after the Qualifying Investment Round. If the qualifying equity financing round was not the last financing round, please provide also the most current cap table.	CompanyName_ THI26_Financial template
4	CVs of the founders, management team and board members.	CompanyName_ THI26_CV_name of person
5	Articles of Association outlining the rights associated with different share classes (such as board representation, voting rights, liquidation preferences, anti-dilution protections, protective provisions, and other potential provisions).	CompanyName_ THI26_AoA

#	Document name	File name
6	Qualified Investment Round supporting information and documents: • Public link to press release of the Qualified Investment Round, if applicable. • Board resolution approving the Qualified Investment Round or similar documentation as proof. • Official corporate documentation confirming the capital increase (e.g. commercial register extract, notarised resolution or equivalent filing). • Amount raised in the Qualified Investment Round. • Name of the qualified privately managed, profit-oriented professional investor participating in the Qualified Investment Round.	CompanyName_ THI26_QIR_name of document
7	Documentation of any additional Capital injections in the company (if any) in any form – equity, convertibles/SAFEs or similar instruments, executed after the Qualifying Investment Round.	CompanyName_ THI26_form of capital injection (to be named case by case)
8	Detailed explanation and definition of the governance framework for potential subsidiaries or dependent entities under the legal entity, including roles, responsibilities, decision-making processes, and compliance mechanisms. In case of a holding structure, please provide up-to-date corporate chart (showing holding, operating entities, non-EU subsidiaries, shareholder base) and evidence of structural link (e.g. shareholder register, extract from trade register). Include any intercompany agreements (IP, cost-sharing, loans), if applicable.	CompanyName_ THI26_Governance

3.3.1 Innovation Maturity Level

Solutions must be at the Innovation Maturity Levels (IML) listed below, depending on their industry focus:

- IML ≥ 5 for Biotech (Safety/Toxicity study stage).
- IML≥ 6 in Medtech (Initial clinical PoC).
- IML ≥ 7 for Digital (Market validation).
- IML ≥ 7 for Biomarker Diagnostics.

Please refer to EIT Health's Healthcare Innovation Cycle Framework for more information on the required Innovation Maturity Level for this call to ensure appropriate assessment of your solution's IML - https://eithealth.eu/a-framework-for-innovation-in-healthcare/.

3.3.2 Project duration

Projects must not run longer than 12 months, with an effective start date on 1 January 2027.

3.4 Funding Conditions for Applications

3.4.1 Maximum EIT Health funding

Projects may request between 300,000 and 500,000 EUR in EIT Health funding.

3.4.2 Co-funding requirements

EIT Health will fund a maximum of 50% of the project's total costs. The company must secure the remaining 50% co-funding from other sources.[11]

Project's total costs = EIT Health funding + Co-funding.

3.4.3 Budget submission

To assess the co-funding requirement, the project budget submitted must include the total project costs, not just a budget covering the EIT Health funding.

3.4.4 Cost eligibility

Eligible costs must follow those as set out in the Horizon Europe model grant agreement.[12] Subcontracting is permitted in the Horizon Europe model grant agreement. However, for this call subcontracting costs must cover only a limited part of the action and cannot replace the beneficiary's own capacity to implement the project and achieve impact. Applications with a high proportion of subcontracting costs in their budget are unlikely to be evaluated positively. In the case of a holding structure, only the cost incurred under the awarded beneficiary will be eligible.

---

[11] This grant cannot be combined with other funding from the European Institute of Innovation and Technology and its associated Knowledge Innovation Communities (KICs)

[12] See Article 6 – Eligible and Ineligible Costs and Contributions - https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/common/guidance/aga_en.pdf

3.5 EU Restrictions on Participation

3.5.1 EU restrictive measures

Entities subject to EU restrictive measures under Article 29 of the Treaty on the European Union (TEU) and Article 215 of the Treaty on the Functioning of the EU (TFEU)[13] as well as Article 75 TFEU[14], are not eligible to participate in any capacity, including as beneficiaries, affiliated entities, associated partners, third parties giving in-kind contributions, subcontractors or recipients of financial support to third parties (if any). Special rules also apply to entities covered by Commission Guidelines No 2013/C 205/0522[15].

3.5.2 Legal entities established in Russia, Belarus, or in non-government-controlled territories of Ukraine

Given the illegal invasion of Ukraine by Russia and the involvement of Belarus, there is currently no appropriate context allowing the implementation of the actions foreseen in this programme with legal entities established in Russia, Belarus, or in non-government-controlled territories of Ukraine. Therefore, even where such entities are not subject to EU restrictive measures, such legal entities are not eligible to participate in any capacity. This includes participation as beneficiaries, affiliated entities, associated partners, third parties giving in-kind contributions, subcontractors or recipients of financial support to third parties (if any). Exceptions may be granted on a case-by-case basis for justified reasons.

With specific regard to measures addressed to Russia, following the adoption of the Council Regulation (EU) 2024/1745 of 24 June 2024[16] (amending Council Regulation (EU) No 833/2014 of 31 July 2014) concerning restrictive measures in view of Russia's actions destabilising the situation in Ukraine, legal entities established outside Russia but whose proprietary rights are directly or indirectly owned for more than 50% by a legal person, entity or body established in Russia are also not eligible to participate in any capacity.

3.5.3 Measures for the protection of the Union budget against breaches of the principles of the rule of law in Hungary

Following the Council Implementing Decision (EU) 2022/2506, as of 15 December 2022, no legal commitments can be entered into with Hungarian public interest trusts established under the Hungarian Act IX of 2021 or any entity they maintain. Affected entities may continue to apply to calls for proposals and can participate without receiving EU funding, as associated partners, if allowed by the call conditions. However, as long as the Council measures are not lifted, such entities are not eligible to participate in any funded role (beneficiaries, affiliated entities, subcontractors, recipients of financial support to third parties, etc.). In case of multi-beneficiary grant calls, applicants will be invited to

---

[13] Please note that the EU Official Journal contains the official list and, in case of conflict, its content prevails over that of the EU Sanctions Map

[14] Please note that the EU Official Journal contains the official list and, in case of conflict, its content prevails over that of the EU Sanctions Map

[15] Commission guidelines No 2013/C 205/05 on the eligibility of Israeli entities and their activities in the territories occupied by Israel since June 1967 for grants, prizes and financial instruments funded by the EU from 2014 onwards (OJEU C 205 of 19.07.2013, pp. 9-11)

[16] OJ L 229, 31.7.2014, p. 1–11

remove or replace that entity in any funded role and/or to change its status into associated partner. Tasks and budget may be redistributed accordingly.

3.5.4 Restrictions for the protection of European communication networks

The protection of European communication networks has been identified as an important security interest of the Union and its Member States[17]. For further information, please refer to the Horizon Europe, Work Programme 2025, General Annexes, B – Eligibility on page 14[18].

3.6 Applicant Exclusion Criteria

Applicants will be excluded from participation in the Call and from the award if they are in one of the situations referred to in Article 138(1) of the EU Financial Regulation. Applicants may not participate in this call that are subject to EU administrative sanctions (i.e. exclusion) or are in one of the following exclusion situations that bar them from receiving EU grants:

- bankruptcy, winding up, affairs administered by the courts, arrangement with creditors, suspended business activities or other similar procedures (including procedures for persons with unlimited liability for the applicant's debts);
- they are in breach of social security or tax obligations (including if done by persons with unlimited liability for the applicant's debts);
- they are guilty of grave professional misconduct (including if done by persons having powers of representation, decision-making or control, beneficial owners or persons who are essential for the award/implementation of the grant);
- they are guilty of fraud, corruption, having links to a criminal organisation, money laundering, terrorism-related crimes (including terrorism financing), child labour or human trafficking (including if done by persons having powers of representation, decision-making or control, beneficial owners or persons who are essential for the award/implementation of the grant);
- they have shown significant deficiencies in complying with their main obligations under an EU procurement contract, grant agreement, prize, expert contract, or similar (including if done by persons having powers of representation, decision-making or control, beneficial owners or persons who are essential for the award/implementation of the grant);
- they are guilty of irregularities within the meaning of Article 1(2) of Regulation No 2988/9534 (including if done by persons having powers of representation, decision making or control, beneficial owners or persons who are essential for the award/implementation of the grant); or
- they have created under a different jurisdiction an entity with the intent to circumvent fiscal, social or other legal obligations in the country of origin or created another entity with this purpose (including if done by persons having powers of representation, decision-making or control, beneficial owners or persons who are essential for the award/implementation of the grant).

---

[17] European Council conclusions of 1 and 2 October 2020 (EUCO 13/20), point 11; Council Conclusions on the significance of 5G to the European Economy and the need to mitigate security risks linked to 5G, 14517/19.
[18] https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/horizon/wp-call/2025/wp-14-general-annexes_horizon-2025_en.pdf

- Have misrepresented the information required as a condition for participating in the procedure or have failed to supply that information; or,
- were previously involved in the preparation of documents used in the award procedure where this entails a breach of the principle of equality of treatment, including distortion of competition, that cannot be remedied otherwise.

As evidence, the applicants will have to submit a declaration of honour on exclusion criteria and absence of conflict of interest. Failure to provide adequate documentation may result in the exclusion of the applicants concerned.

3.7 Contracting Requirements for Successful Applicants

The following contracting obligations and requirements must be fulfilled by each company to receive funding.

- Signature of the Financial Support Agreement (FSA)
- Having a registered and validated Participant Identification Code (PIC)[19]
- Signature of the Grant-to-Options-to-Equity Agreement [20]
- Settlement of any open balance with EIT Health (e.g. due invoice)

3.7.1 Legal Entity and Financial Capacity Check

Successful applicants may go through a legal entity validation process known as the Partners Validation Service. This process requires a valid PIC code. The lack of a code can lead to significant delays in the release of funding. The Partners Validation Service will request registration documents and a signed Declaration of Honour from successful applicants.[21] The validation may also include a check of the successful applicants by the EIT in the Early Detection and Exclusion System (EDES) of the European Commission.

Applicants must have stable and sufficient resources to successfully implement the projects and contribute to their share. In accordance with Article 27 of the Horizon Europe Regulation, the financial capacity shall be verified for the coordinator if the requested funding is equal or greater than 500,000 EUR. If there are grounds to doubt the financial capacity of an applicant, EIT Health shall also verify the financial capacity of the applicant, or of the coordinator even where the requested funding is below the threshold referred to above. If requested by EIT Health, successful applicants will go through a financial capacity check as part of the Partners Validation Service.

[19] Register your organisation in the EU Funding & tender opportunities portal to obtain the nine-digit Participant Identification Code (PIC number). If you do not know if your organisation already has a PIC number, you can verify directly on the EU Portal (click here) whether your organisation is already registered.
[20] See section 3.9 on Financial Sustainability Conditions for further information
[21] The Partners Validation Service is a shared service used by all EIT KICs. The service is operated by EIT Urban Mobility.

3.8 Grant Payment Mechanism for Successful Applicants

Funding will be provided via the cost reporting model.[21] The disbursement of EIT funds to subgrantees (a subgrantee is a successful applicant) is made in two payments for each year of operation: the pre-financing payment and the annual-balance payment.

1. The pre-financing payment is made to the subgrantee for each project for each year. The first pre-financing payment will be made within three months following the signature of all contracts and kick-off of the project. A subgrantee will receive as many prefinancing payments as the number of projects it participates in each year. The pre-financing payment may amount to a maximum of 25% of the EIT financial support amount a subgrantee has been allocated in the grant management system for the year N (e.g. 2026 or 2027 or 2028 respectively) by the time of the execution of the payment. The exact percentage amount is communicated in due course to subgrantees by the time of the execution of the payment. For Small and Micro Enterprises, additional pre-financing payments will be established up to a yearly maximum of 80% of the annual EIT grant for each year.

2. The annual balance payment is released within three months of the cost reporting / cost check / CFS audit, and at the latest September of the year N+1. This payment is made to each subgrantee for each project. This means that a subgrantee receives one annual balance payment per project calculated using the total accepted EIT financial support amount and the sum of all pre-financing payments received for each project in which it has participated. This payment is contingent upon the result of the performance assessment during the reporting phase. Both payments are communicated in due time to the Master contact and Legal and Finance contacts registered in our grant management system.

Above and beyond the specific EIT Health rules of participation, all activities must comply with the relevant Horizon Europe and EIT financial and legal framework considerations.

For further details on project implementation and the disbursement of funding, please see the EIT Health Project Implementation Handbook.

3.9 Financial Sustainability Conditions for successful applicants

All projects awarded EIT Health funding must contribute to the long-term financial sustainability of EIT Health and its ecosystem.

As a condition of funding, the company receiving the grant must contribute to the financial sustainability of EIT Health. This is achieved through the Grant-to-Options-to-Equity Agreement. This agreement extends beyond the project duration and may have implications for ownership, financing, revenues, and overall strategy. It is important that applicants verify company size, align with stakeholders, and ensure the model fits their long-term strategy. Applicants are expected to fully understand these implications before applying.

The Grant-to-Options-to-Equity Agreement is signed at the time of project contracting and is a pre-requisite to the release of any funding.

Health

Co-funded by the European Union

3.9.1 Grant-to-Options-to-Equity Agreement

The Grant-to-Options-to-Equity Agreement works in the following manner:

- Funding is provided as a grant. Costs incurred must comply with Horizon Europe rules to be eligible. The total grant amount provided to the company after final reporting and balance payment at the end of the project is considered the total amount EIT Health has invested in the company.
- In exchange, EIT Health receives options that may convert into equity in the company at a later stage, either at a set maturity date or if certain predefined events occur (such as an acquisition or change of control).[22]
- Conversion metrics are defined upon the occurrence of certain trigger events:
  - A qualified equity financing round (predefined minimum size, external investors, real equity issuance); or,
  - other predefined liquidity events (e.g., IPO, acquisition or change of control).
- The options have a maturity date; if no trigger occurs before, options are converted into equity.
- Conversion triggers, valuation logic and conditions are predefined, non-negotiable, and linked to the company, not the project.
- If a holding structure applies, EIT Health shall sign the Grant-to-Options-to-Equity Agreement with the parent (holding) company.

You can read the term sheet of the Grant-to-Options-to-Equity Agreement here.[23]

3.10 Project Monitoring During and After the Funding Period

During the funding period, projects will undergo regular monitoring to track progress against the agreed-upon workplan and deliverables as well as cost checks. Project reporting and cost checks take place every six months and enable EIT Health to maintain a good overview of the activities. Activity Leaders are asked to report the progress of their deliverables, milestones and KPIs in a dedicated online platform, along with submitting a bi-annual cost report to ensure eligibility of costs (see section 3.7). EIT Health monitoring principles and obligations are governed by the Horizon Europe MGA, Annex 5. [24]

3.10.1 Monitoring during the funding period

Each activity is required to fill in one year-end report for each year of project duration (i.e., projects spanning from any month in 2026 to December 2028 must fill in three separate annual reports). The process serves to either fast-track (see section 3.10), support, redirect, or stop the activity in cases of improper implementation or severe underperformance.

---

[22] Please see the Grant-to-Options-to-Equity Agreement template for the definition of these predefined events.

[23] See 'Contract Templates' folder

[24] general-mga_horizon-euratom_en.pdf (europa.eu).

The Final Performance report will be a compilation of all performance reports submitted. Performance reporting serves as the basis for activity monitoring, which may take place directly after a performance report has been submitted. As such the information provided in the performance report largely informs the monitoring meeting between the project and representatives of EIT Health. Please refer to the Implementation Handbook for further information.

Submission of activity reports and attendance of monitoring meetings are the responsibility of the Activity Leader. For projects awarded funding under the Transformative Health Instruments Call, the Activity Leader must be present at all monitoring meetings. EIT Health recommend that one member of the project management team and one technical project member attend these meetings to answer questions on both the management and technical areas of the project.

3.10.2 Post-funding monitoring

Post-funding monitoring is required for up to three years after activity closure, possibly longer if required by the Grant-to-Options-to-Equity Agreement. Post-funding monitoring will be light in format and aims to capture the project’s impact beyond the period of EIT Health funding. This helps identify success stories, capture key learnings, and evaluate the use of public funding against EIT Health’s and Horizon Europe’s strategic goals.

3.11 Fast Track Mechanism and Additional Project Funding

Projects selected under this Call that demonstrate exceptional performance and high strategic value may be eligible for additional funding from EIT Health via the Fast Track mechanism. EIT Health may, at its own discretion and subject to available budget, provide extra grant funding to projects in its portfolio to maximize the impact of EIT Health's portfolio and seize time-sensitive opportunities. Successful execution and completion of a project will not guarantee Fast Track funding. Eligibility is strictly reserved for projects or entities that:

- **Exceed Expectations:** Have successfully achieved all original milestones in a timely manner.
- **Justify Necessity:** Can demonstrate a critical need for continued public funding to address specific market failures or regulatory hurdles (e.g., unexpected regulatory changes, opportunity to expand to high-impact patient populations).
- **Strategic Alignment:** Align with the specific strategic priorities of EIT Health at the time of the Fast Track decision.

3.11.1 Evaluation process for the Fast Track mechanism

To access additional support, existing projects in the EIT Health portfolio will be required to present their case for additional support and submit a workplan and demonstrate the expected impact of the additional support requested.

Fast-tracked proposals will be subject to a specialised, expedited evaluation procedure involving an assessment by EIT Health and independent external experts against standard Horizon Europe criteria (Excellence, Impact, Implementation) and financial sustainability contribution potential.

The new project proposal and budget would be considered and linked to the financial sustainability of the KIC with a renewed or fully new financial sustainability contribution agreement (Grant-to-Options-to-Equity Agreement) signed. This last step
could lead to the need to perform an updated due diligence analysis and validation on those companies engaging in those agreements.

4 Application Process

All application materials must be submitted via the EIT Health application platform.

We strongly advise applicants to familiarise themselves with EIT Health application platform before beginning their application, and to begin the application process on the platform at least one week before the deadline.

4.1 Key Timeline

Milestone	Date	Description
Call Launch	**24 June 2026**	Publication of the Call Document and opening of the application process.
Call Presentation Webinar	**15 July 2026**	Presentation of the Call scope, objectives, and application platform.
Open for applications	**15 July 2026**	Application platform opens for submissions
Q&A Sessions	**02 September 2026**	Open Q&A session for applicants to ask questions before deadline.
Proposal Submission Deadline	**16 September 2026, 16.00 CEST**	Strict deadline for application submissions. Late submissions will not be considered.
Evaluation: Eligibility notification	**07 October 2026**	Yes/no decision on proposal meeting eligibility requirements.
Evaluation: Remote evaluation	**08 – 27 October 2026**	Remote evaluation of all eligible applications.
Evaluation: Notification of remote evaluation outcome and invite to pitches	**28 October 2026**	Communication of remote evaluation results and invitation to a final pitching session for up to top 15 proposals with a score of 70% or higher.
Evaluation: Pitches	**06 – 19 November 2026**	Online pitching sessions in front of a panel of external and internal evaluators.
Final Award Notification	**09 December 2026**	E-mail notification of final results.
Standstill Period	**09 December – 09 January 2027**	Preparation of grant agreements

Milestone	Date	Description
Project Contracting	**01 January 2027**	Registration and validation of all applicants in the Grant Management System, signature of all agreements, and PIC number validation.
Start Date of Project Activities	**01 January 2027**	Official commencement of funded projects.

4.2 Use of Artificial Intelligence

Applicants may use generative AI tools to assist in drafting funding proposals. All AI-generated content must be handled with caution, responsibility, and full transparency. Below are EIT Health's guidelines that applicants should consider when using generative AI tools to build a proposal:

- **Review & validate:** Critically check AI output for factual accuracy, relevance, and alignment with the call's objectives.
- **Verify citations:** Cross-check any references suggested by AI; remove or correct any that are fabricated or incorrect.
- **Ensure originality:** AI may mirror existing sources—applicants must avoid plagiarism by properly attributing all material.
- **Disclose usage when advisable:** Clearly state which AI tools were used and how.
- **Respect IP & privacy:** Do not include copyrighted or proprietary material without authorization; review AI platform terms and avoid submitting confidential or sensitive data to AI tools, unless data protection standards (e.g. GDPR) are met.

Applicants remain entirely accountable for every part of their proposal, including AI-produced text.

5 Evaluation Procedure

5.1 Evaluation Process

The selection process is a single-stage submission followed by:

5.1.1 Admissibility and eligibility, exclusion and selection stages

1. **Admissibility and Eligibility Check:** Formal verification of application admissibility and eligibility status according to the requirements of the Call. See chapters 3.1, 3.2, 3.3, and 3.4 on application conditions.

5.1.2 Evaluation of proposals

2. **Remote Evaluation:** Three external independent experts will evaluate each submitted application and provide feedback and a score based on the evaluation criteria stated in section 5.3 below.

   Up to 15 shortlisted candidates who score at least 70 / 100 will be invited to the online pitches.

3. **Online Pitching:** Teams are invited to pitch their proposals at an online pitch session to a panel five experts; three external independent experts and two EIT Health management staff. Panel members will all be present in the same location at EIT Health's headquarters.

   The external independent experts participating in the panel evaluation are different from those involved in the remote evaluation stage and will not have reviewed any applications during that earlier phase. In accordance with the evaluation criteria (see section 5.2), each panel member independently assesses and scores the proposals based on the submitted application, the pitch presentation, and the answers provided during the question and answers section of the pitch session.

   Applicants are expected to ensure their availability for the pitching sessions and to accept the pitching date and time assigned if invited to a pitching session. EIT Health will not be able to rearrange pitching slots according to the availability of applicants.

4. **Ethical Legal Social Issues Review:** The Ethical, Legal, and Social Issues (ELSI) review will aim to ensure that all elements in the proposal linked to critical ethical, legal and social considerations are well defined and addressed, thereby helping to de-risk the EIT Health portfolio.

5. **Final Selection notification:** EIT Health management makes the final funding decision based on expert recommendations, online pitching scores, and available funding. Only applicants with an online pitching score of at least 70/100 will be considered for funding. All applicants will be notified of the final outcome and receive feedback from each expert in accordance with the timetable in section 4.1 above.

5.2 Evaluation methodology

5.2.1 Remote evaluation methodology

Each application will be reviewed by a panel of three external experts in accordance with the evaluation criteria (section 5.3). Each application will receive a single score and feedback on the application from each panel member who reviewed the application. Final scores for each application will be out of 100 and are calculated by taking the mean of the three reviewers' scores.

Applications will then be ranked from highest scoring to lowest scoring. Up to the top 15 applications that score 70 / 100 or more will then be selected to proceed to the online pitches.

5.2.2 Online pitching evaluation methodology

Up to 15 shortlisted candidates who score at least 70 / 100 in the remote evaluation step will be invited to the online pitches.

Pitching sessions will consist of a pitch and a question and answers session. Each evaluation panel member will evaluate proposals based on a review of the submitted application, the pitch, and the answers to the question and answers session. The evaluation panel will consist of five experts; three external independent experts and two EIT Health management staff.

Each application will receive a single score and feedback on the application from each panel member. Final scores for each application will be out of 100 and are calculated by taking the mean of the five reviewers' scores with respective criteria weighting taken into account.

Scores from the remote evaluation are not accounted for during the online pitches. Because the pitching sessions allow panel members to go into further detail into the application, it is likely that the online pitching feedback may differ from the remote evaluation feedback.

5.2.3 Evaluation final outcome

Following the online pitching sessions, applications will be ranked from highest scoring to lowest scoring based on the online pitching scores only. Up to the top ten applications that score 70 / 100 will be selected for funding and invited to the contracting stage (section 3.6).

5.3 Evaluation Criteria

Proposals will be assessed via criteria consistent with Horizon Europe standards and specific to the EIT Health mission and financial sustainability. The table below provides a description of these criteria, the evaluation stage at which they apply, and the respective weights of each criteria in their contribution to the final score of each stage.

5.3.1 Remote evaluation criteria

The below table details the evaluation criteria for the remote evaluation stage. To pass through to the pitch evaluations, applicants must score at least 10% of the total score in each evaluation criteria, and at least 70% overall.

Evaluation Criteria	Description	Weight
Excellence	Applications must demonstrate: • The innovation is technically and clinically novel. • A clear and substantial unmet patient and healthcare need. • An improved, unique, or novel solution exhibiting a clear patient benefit compared to what is on the market. • High scientific quality and technical/clinical development plan. • An accurate assessment of the current and forecasted IML levels. • A well-reasoned explanation of how gender has been accounted for in the project.	20%
Impact	The proposed innovation has the potential to create significant value for European citizens and healthcare systems. Focus on the ambition and feasibility of the projected results of the project, in particular the future launch to the market of the solution and the contribution to the 150,000-patient impact target. Applications must demonstrate: • The desired impact is clear, ambitious, and achievable. • The key performance indicators are relevant to the desired impact, and are specific, measurable, and achievable.	20%
Quality and Efficiency of Implementation	The project management plan and allocation of resources is appropriate and realistic, including budget planning and risk assessment Applications must demonstrate: • A clear, reasonable, and appropriate workplan • A comprehensive and reasonable risk assessment • A reasonable and sufficient budget	20%
KIC Portfolio Strategic Fit and Compliance with the Financial Sustainability Principles	The application clearly aligns with the aims of the call. The proposed innovation is backed by a robust commercial entity and strategy, demonstrating solid future market and growth potential in the EU. Applications should substantiate significant EU target market size and attractiveness, a strong business model and commercial exploitation plan, investor traction, company potential, and a clear growth plan for achieving scalability and to fulfil the terms outlined in the Grant-to-Options-to-Equity Agreement. Applications must demonstrate: • A strong alignment with the aims of the call and activities being called for.	40%

Evaluation Criteria	Description	Weight
	• An experienced and capable management team with relevant experience and capability to support growth. • A high-quality Intellectual Property Strategy. • A clear and effective governance and ownership structure that does not conflict with the Grant-to-Options-to-Equity Agreement. • No significant legal or compliance risks. • Professional investor commitment. • Healthy and realistic financial performance that supports the Company's long-term viability and growth. There should be a clear trend of revenue growth and profitability. Cost management should be efficient, and financial practices should be sustainable objectives. • A realistic value creation plan.	

5.3.2 Pitches Evaluation Criteria

The below table details the evaluation criteria for the pitch evaluation stage for applications. To be considered for funding, applicants must score at least 10% of the total score in each evaluation criteria, and at least 70% overall.

Evaluation Criteria	Description	Weight
Excellence	Applications must demonstrate: • The innovation is technically and clinically novel. • A clear and substantial unmet patient and healthcare need. • An improved, unique, or novel solution exhibiting a clear patient benefit compared to what is on the market. • High scientific quality and technical/clinical development plan. • An accurate assessment of the current and forecasted IML levels. • A well-reasoned explanation of how gender has been accounted for in the project.	25%
Impact	The proposed innovation has the potential to create significant value for European citizens and healthcare systems. Focus on the ambition and feasibility of the projected results of the project, in particular the future launch to the market of the solution and the contribution to the 150,000-patient impact target.	15%

Co-funded by the European Union

Evaluation Criteria	Description	Weight
	Applications must demonstrate: • The desired impact is clear, ambitious, and achievable. • The key performance indicators are relevant to the desired impact, and are specific, measurable, and achievable.	
Quality and Efficiency of Implementation	The project management plan and allocation of resources is appropriate and realistic, including budget planning and risk assessment Applications must demonstrate: • A clear, reasonable, and appropriate workplan • A comprehensive and reasonable risk assessment • A reasonable and sufficient budget	15%
KIC portfolio strategic fit and compliance with the financial sustainability principles	The application clearly aligns with the aims of the call. The proposed innovation is backed by a robust commercial entity and strategy, demonstrating solid future market and growth potential in the EU. Applications should substantiate significant EU target market size and attractiveness, a strong business model and commercial exploitation plan, investor traction, company potential, and a clear growth plan for achieving scalability and to fulfil the terms outlined in the Grant-to-Options-to-Equity Agreement. Applications must demonstrate: • A strong alignment with the aims of the call and activities being called for. • An experienced and capable management team with relevant experience and capability to support growth. • A high-quality Intellectual Property Strategy. • A clear and effective governance and ownership structure that does not conflict with the Grant-to-Options-to-Equity Agreement. • No significant legal or compliance risks. • Professional investor commitment. • Healthy and realistic financial performance that supports the Company's long-term viability and growth. There should be a clear trend of revenue growth and profitability. Cost management should	45%

Evaluation Criteria	Description	Weight
	be efficient, and financial practices should be sustainable objectives. • A realistic value creation plan.	

5.4 Communication of evaluation results to applicants

Following the award decision, all applicants will be informed of the result in writing via email from the application platform. All applicants will receive their overall score, and feedback from each panel member. It is important that all emails with the @eithealth.eu domain are added to the safe senders list for all applicants so that critical emails do not get sent to the spam folder.

Applicants may request further clarification regarding the evaluation result via email. EIT Health will aim to reply to such requests within 15 days. Where this is not possible, EIT Health will inform the applicant requesting clarification with an estimated response time.

5.5 Requirements for selected proposals

If the proposal is selected, subsequent communications may include a set of recommendations or conditions as a result of the outcome of the evaluation. These requirements may not entail a substantial modification of the proposal.

Such communications will establish a clear and non-negotiable deadline for the submission of the adjusted proposals.

Should all conditions be met within the established deadline, EIT Health will initiate the financial support agreement preparation process/onboarding (e.g. legal entity validation, signature of Declaration of honour, if not yet provided, financial capacity check, if relevant).

If the applicant fails to comply with the provided recommendations/conditions or does not respond in the time allocated, EIT Health reserves the right to withdraw the conditional notification.

If an applicant with a provisional award for funding fails to sign all required agreements, EIT Health may use the final ranking list as a reserve list. EIT Health may decide to contact the next application in the final ranking list, as long as this application scored at least 70 / 100, to provisionally award them funding. This may happen up to four months after the outcome notification.

5.6 Standstill Period

Following final outcome notification, a standstill period will begin (09 December 2026 to 01 January 2027). During this time no contracts will be signed, however this time may be used to review and prepare contracts for signature from 01 January 2027.

5.7 Publication of Call Results

EIT Health may make available via its website, information on the call results and the recipients of funds from this call.

The following information shall be published, having due regard for the requirements of confidentiality and security, in particular the protection of personal data:

- the recipient's full legal name and the country where it is established;
- the amount committed and, in case of a commitment with multiple recipients, the breakdown of this amount per recipient where available;
- subject of grant or contract.

6 Grounds for Appeal and Appeal Procedure

Applicants may appeal the outcome of their application of their own proposal in line with the EIT Health Appeals procedure. The only grounds for appeal are as follows:

- Process errors.
- Technical problems beyond the control of applicants (e.g. the technical failure of the electronic submission system).
- Human/technical errors made by EIT Health staff.
- If you consider that you have been adversely affected by a particular decision not following EIT Health's Code of Conduct.

What does NOT constitute grounds for an appeal:

- Scores awarded in the course of the proposal evaluation process (unless these go against our Code of Conduct).

6.1.1 Appeals Procedure

- Applicants should send their appeals in writing to appeals@eithealth.eu as soon as they identify an error, but no later than 21 days after the error occurred.
- EIT Health assesses the claim and delivers a first response
- If there are grounds for appeal, EIT Health will attempt to remedy the consequences (e.g. if a technical error of EIT Health prevented the submission of a proposal or application, a late submission may still be accepted as eligible)
- The Head of Compliance, and where applicable, Supervisory Board is notified about the matter if:
    - the applicant does not accept a rejection of the appeal, or
    - there are grounds for appeal, but the problem cannot be remedied any more without disrupting the process

7 Where to Get Help

We aim to make the application process as clear and accessible as possible. If you have questions regarding the EIT Health Innovation Validation Call 2026, please consult the following resources:

7.1 Call Information Webinars

We offer two distinct online sessions to guide applicants:

Session	Purpose	Date & Access
Call Presentation Webinar	Comprehensive introduction to the Call's objectives, scope, and the funding model.	**15 July 2026, 13.30 CEST** Click here to register
Final Q&A Sessions	A dedicated session to answer specific, detailed questions from applicants who are finalising their proposals.	**02 September 2026, 11.00 CEST** Click here to register

7.2 Frequently Asked Questions (FAQ)

A comprehensive Frequently Asked Questions (FAQ) document is available, covering common questions on eligibility, budget preparation, and the evaluation process. We recommend consulting this document before submitting your formal application.

- **Access Link:** FAQ Document

7.3 Contact for Support

For general administrative queries, questions about the application platform, or technical issues with the submission process, please contact the EIT Health directly:

- **Email:** calls@eithealth.eu – please include the call code: "THI" and your application reference code in the subject line of all correspondence.

8 Other Terms and Conditions

8.1 Acceptance of the call conditions

EIT Health reserves the right to make reasonable amendments and additions to the call conditions. Amendments and additions to the call conditions shall be valid only before the submission deadline, and if made available to all potential applicants at the same time via this call document and any relevant call documents.

EIT Health may declare the call unsuccessful in the case where zero applications are received, if the applications do not meet the admissibility, eligibility, exclusion and selection criteria, or if none of the applications reach the score thresholds laid down in this call text.

By submitting the application form, the applicant agrees to the present call conditions. Applicants agree that they have no legal entitlement to funding.

8.2 Cancellation of the call

EIT Health reserves the right to cancel the call at any time before the signature of the Financial Support Agreement(s) without the obligation to compensate applicants, in particular where its objectives can no longer be met, provided that the applicants are informed in a transparent manner in writing as follows:

- if the cancellation takes place before that award: on the call page of https://eithealth.eu/
- if the cancellation takes place following the communication of the results to the applicants, during the standstill period, or anytime before the signature of the Financial Support Agreement: in writing directly to the selected applicants.

8.3 Data Protection

EIT Health ensures that any processing of personal data shall be performed in accordance with Regulation (EU) 2016/679 of the European Parliament and of the Council of 27 April 2016, on the protection of natural persons with regard to the processing of personal data and on the free movement of such data, and in accordance with Directive 95/46/EC (General Data Protection Regulation). As a data subject, you have the right of access, the right to rectification, the right to erasure, the right to restrict processing, the right to data portability, the right to object, and the right not to be subject to a decision based solely on automated processing. If you have a question about personal data processing or want to exercise your data subject rights, you can contact our Data Protection Officer at DataPrivacy@eithealth.eu.

The collected personal data will be used solely for the evaluation of the applications and the conduct of the call process. The data controller is EIT Health.

Personal data will be deleted five years after the announcement of the results of the call in case of unsuccessful applications and seven years for successful applicants.

By submitting your application to this call, you consent that EIT Health will collect, transfer, process, store, and delete your data in accordance with the aforementioned conditions.

For more information on the processing of your personal data as part of an application to this call, please consult the Legal notice and Terms of use of EIT Health's online application management platform. You can also read EIT Health's online privacy statement at: https://eithealth.eu/privacy-policy/.

8.4 Confidentiality

EIT Health undertakes to use any confidential information shared by the applicants solely for the purposes of the evaluation process.

Confidential information shall mean data and/or information (in any form) that is proprietary to, or possessed by, the applicants and not generally known to the public, or that has not yet been revealed whether in tangible or intangible form, that is identified as confidential in writing or when disclosed orally.

Confidential information included in the application form must be expressly labelled by the applicant as such in the form. As regards confidential information expressly labelled as such in the call process, EIT Health undertakes to (i) not disclose them in any way and any form, without the prior written authorization of the applicant; and (ii) not to use them for purposes other than those strictly necessary for participation in the call.

Confidential information may be shared among EIT Health and its subsidiaries (e.g. KIC Co-Location Centres) solely for the purposes of the call process. EIT Health undertakes to impose this confidentiality obligation on its employees and the employees of its subsidiaries and its collaborators, as well as on independent experts and all subjects who, by virtue of participating in the conduct of the call, including as members of the Evaluation Committee, may have access to such confidential data and information.

The applicants agree that data and information regarding the selected projects' implementation (e.g. success stories) not labelled as confidential may be disclosed in connection with the activities of EIT Health.

8.5 Avoidance of conflict of interest

EIT Health is committed to ensure the avoidance of conflict of interest (regarding all actors) and comply with the principles of transparency, non-discrimination and sound financial management.

Measures to avoid potential Conflict of Interest or unequal treatment of applicants are ensured including through appropriate conflict of interest declaration and assessment process, established written communication channels and independent and fair complaints/redress procedures.

In case an applicant becomes aware of a potential conflict of interest affecting the conduct of the call process, it shall notify the EIT Health of the conflict of interest without any delay.

8.6 Ethics and values

The proposal must comply with:

- ethical principles (including the highest standards of research integrity); and,
- applicable EU, international and national law, including the Charter of Fundamental Rights of the European Union and the European Convention for the Protection of Human Rights and Fundamental Freedoms and its Supplementary Protocols.

No financial support/ funding can be granted, within or outside the EU, for activities that are prohibited in all Member States. No financial support/ funding can be granted in a Member State for an activity which is forbidden in that Member State.

Please refer to the financial support agreement for further requirements.

8.7 Intellectual property rights

Applicants retain full and exclusive ownership of their prior information and intellectual property rights. By submitting their application, applicants confirm that they own or lawfully hold, and have secured or will secure in due time, all rights and permissions necessary to use all elements of the innovative product or service included in their application, or that they will take appropriate measures to secure and protect such rights during the project. Applicants agree to indemnify and hold harmless EIT Health, the EIT, and/or any assignee or affiliate from any third-party allegations or claims of intellectual property rights infringement by the product or service of applicants. Applicants shall have the right to further develop, use and license their intellectual property rights for creating, making, marketing, and distributing products, services, and technology. Applicants agree to respect the IPR (Intellectual Property Rights) Rules (Article 16) of the Model Grant Agreement and Article 10 of the Financial Support Agreement (Common Subgrant Agreement Model).

8.8 Withdrawal of the funding – Recovery of undue amounts

EIT Health may withdraw the funding after its award and recover all payments made in line with the provisions of the Financial Support Agreement (Article 7.4.), including in the following cases:

- in case the applicant committed substantial errors, irregularities or fraud;
- in case the applicant committed serious breach of obligations under the Financial Support Agreement or during its award (including non-compliance with the call conditions, submission of false information, failure to provide required information, etc.)
- it is established that the awarded applicants were not eligible or should have been excluded.

8.9 Checks, reviews, audits and investigations

EIT Health retains the right to initiate checks, reviews and audit on an applicant that has been awarded funding, to verify compliance with the requirements of the call conditions and of the legal and contractual framework referred to above.

EIT Health may request any information and data from applicants that have been awarded funding for five years after completion for these purposes, as well as in relation to monitoring by the EIT.

In accordance with the Grant Agreement between the EIT and the KIC as well as the Financial Support Agreement, the EIT and/or the Commission, the European Anti-Fraud Office (OLAF), the European Public Prosecutor's Office (EPPO) and the Court of Auditors may carry out checks, reviews, audits and investigations in relation to the call and the implementation of the projects.

8.10 Applicable law

The present call is governed by the applicable European Union legal framework (i.e. in particular the EIT Regulation[25], the EU Financial Regulation[26], the Horizon Europe Regulation[27]), supplemented if necessary by the national law of Belgium.

The applicants agree to observe the obligations outlined in the Partnership Agreement and the Grant Agreement signed between the EIT and EIT Health. Applicants agree to comply with the terms of the Model Financial Support Agreement between successful applicants and EIT Health, available here.[28]

8.11 Settlement of disputes

All disputes arising out of or in connection with this Agreement, which cannot be solved amicably, shall be finally settled before the courts of Brussels.

8.12 Marketing, Communication, Dissemination and Visibility

Article 17 of the Horizon Europe Model Grant Agreement requires that beneficiaries must promote the project and its results through strategic, coherent, and effective communications. Any such communications must be factually accurate, and communication materials must acknowledge EU support and display the European flag and funding statement.[29]

Article 17 of the Horizon Europe Model Grant Agreement requires also requires beneficiaries to inform EIT Health as the granting authority before any communication or dissemination activities take place.

[25] Regulation (EU) 2021/819
[26] Regulation (EU, Euratom) 2024/2509
[27] Regulation (EU) 2021/695
[28] See the folder 'Contract Templates'
[29] For specific materials and content to use please see Article 17 of the Horizon Europe General Model Grant Agreement - general-mga_horizon-euratom_en.pdf

Co-funded by the European Union

9 About the EIT

The European Institute of Innovation and Technology (EIT) is a European Union body with a legal personality and a wide legal capacity accorded to legal persons under national law. The EIT was created in 2008 by the European Union (EU) to enhance Europe's global competitiveness by fostering collaboration between businesses, research institutions, and higher education organizations.

The EIT is governed by Regulation (EU) 2021/695 (EIT Regulation), which aligns the EIT's mission with the EU's priorities and the objectives of Horizon Europe on evolving research, innovation, economic growth, job creation, global competitiveness, sustainable growth, higher education and entrepreneurship, by means of the Knowledge and Innovation Communities (KICs), which address specific societal challenges and are established and supported by the EIT.

The EIT Strategic Innovation Agenda (SIA) 2021-2027 is aligned with Horizon Europe and lays down the priority fields and the strategy of the EIT for future initiatives, capacity to generate the best innovation added-value, objectives, key actions, mode of operation, expected results, impact, as well as an estimate of the resources needed for the duration of Horizon Europe.

Horizon Europe Regulation

The Horizon Europe Regulation (EU) 2021/695 foresees that the EIT takes part in the implementation of the Horizon Europe Programme in accordance with its strategic objectives for the period 2021 to 2027, as laid down in the Strategic Innovation Agenda of the EIT, and taking into account the strategic planning of Horizon Europe.

9.1 EIT and Knowledge and Innovation Community (KIC) relations

The EIT Regulation defines KICs, such as EIT Health, as large-scale Institutionalised European Partnerships of higher education institutions, research organisations, companies and other stakeholders in the innovation process in the form of a strategic network, regardless of its legal form, based on joint mid- to long-term innovation planning to meet the EIT's challenges and contribute to attaining the objectives established.

According to the EIT Regulation, and without prejudice to the partnership agreements and grant agreements between the EIT and each KIC, the KICs have substantial autonomy to establish their internal organisation and composition, as well as their agenda and working methods, provided that they result in progress towards achieving the objectives of the EIT and the KICs, taking into account the strategic planning of Horizon Europe and the strategic direction of the EIT set out in the SIA and by the Governing Board.

9.2 Contractual framework between the EIT and the KICs

The long-term relations between the EIT and each KIC are based on a seven-year Partnership Agreement (PA)[30] laying down the general terms and conditions under which the KIC operates as an Institutionalised European Partnership. Subject to positive performance, interim review and outcome of

[30] Model Partnership Agreement: Partnership Agreement

comprehensive assessment of the KIC, the PA can be extended for another period of a maximum of seven years.

The Partnership Agreement between the EIT and EIT Health entered into force on 01 January 2016.

The Grant Agreement (GA)[31] is the contractual instrument laying down the provisions concerning the implementation of the KIC activities (KIC Business Plan, Cross-KIC activities, etc.) through grants, on an annual or multi-annual basis of up to three years with the KICs. Business plans describe the main objectives and expected results and actions taken by the KICs.

The Grant Agreement (2026-2028) between the EIT and EIT Health will enter into force during 2026 and have a retroactive date as of 01 January 2026. The signature of the grant agreement between EIT and EIT Health is a requirement for the disbursement of funding through this call.

9.3 Contractual framework between the KIC and the subgrantees

In accordance with the Grant Agreement (Annex 5), the KIC launches calls (i.e. open calls or KIC partnership calls) to select projects or award prizes. The KIC awards a "financial support to third parties" (i.e. the so called "subgrants" and "prizes") for the implementation of these projects and signs subgrant agreements ("Financial Support Agreements") with the selected entities or consortia.

[31] Horizon Europe Model Grant Agreement: general-mga_horizon-euratom_en.pdf

10 About EIT Health

10.1 Vision and mission

EIT Health was established in 2015, as a ‘knowledge and innovation community’ (KIC) of the European Institute of Innovation and Technology (EIT) as strong, diverse and balanced European Partnership of best-in-class organisations in education, research, technology, business creation and corporate and social innovation.

EIT Health’s vision is ‘To enable people in Europe to live longer, healthier lives by building and growing businesses to create products and services that progress healthcare in Europe, while strengthening our economy and the sustainability of our healthcare systems.’

EIT Health’s mission is: ‘By 2030, we’ll be Europe’s leading innovation platform, facilitating longer, healthier lives and more sustainable healthcare systems.’

10.2 Strategic Objectives

Strengthening healthcare systems in Europe

We want to overcome obstacles to innovation so we can improve healthcare delivery in Europe and make life-changing solutions possible. By working together,
we can remove barriers across borders to create a more resilient and dynamic European healthcare system.

Promoting better health of citizens

European citizens and patients sit at the centre of our organisation. That’s why we’re engaging people at every stage; raising awareness, sharing knowledge and creating tools, treatment and breakthrough solutions which will promote healthy living and active ageing.

Contributing to a sustainable health economy in Europe

We want to create a fertile environment in which innovation can flourish. By building health enterprises and bringing innovative products and services to market, we can create new jobs to grow and strengthen a sustainable European economy.